These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Dowd PM; Martin MF; Cooke ED; Bowcock SA; Jones R; Dieppe PA; Kirby JD Br J Dermatol; 1982 Jan; 106(1):81-9. PubMed ID: 7037038 [No Abstract] [Full Text] [Related]
4. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of Raynaud's phenomenon in scleroderma with a new stable prostacyclin derivative]. Keller J; Kaltenecker A; Schricker KT; Krais T; Schönberger A; Gevatter M; Hornstein OP Dtsch Med Wochenschr; 1984 Sep; 109(38):1433-8. PubMed ID: 6383760 [TBL] [Abstract][Full Text] [Related]
9. Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers. Cruz JE; Ward A; Anthony S; Chang S; Bae HB; Hermes-DeSantis ER Ann Pharmacother; 2016 Dec; 50(12):1060-1067. PubMed ID: 27465880 [TBL] [Abstract][Full Text] [Related]
10. Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin. Shawket S; Dickerson C; Hazleman B; Brown MJ Br J Clin Pharmacol; 1991 Aug; 32(2):209-13. PubMed ID: 1931469 [TBL] [Abstract][Full Text] [Related]
11. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis. Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy of beraprost sodium on Raynaud's phenomenon in patients with systemic sclerosis]. Kaburaki J; Kuwana M; Akizuki M; Takano M; Tojo T Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):29-35. PubMed ID: 7553036 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of Raynaud's syndrome with Iloprost, a chemically stable prostacyclin analogue. Yardumian DA; Isenberg DA; Rustin M; Belcher G; Snaith ML; Dowd PM; Machin SJ Br J Rheumatol; 1988 Jun; 27(3):220-6. PubMed ID: 2454140 [TBL] [Abstract][Full Text] [Related]
14. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967 [TBL] [Abstract][Full Text] [Related]
15. Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. McHugh NJ; Csuka M; Watson H; Belcher G; Amadi A; Ring EF; Black CM; Maddison PJ Ann Rheum Dis; 1988 Jan; 47(1):43-7. PubMed ID: 2449871 [TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained. Kingma K; Wollersheim H; Thien T J Cardiovasc Pharmacol; 1995 Sep; 26(3):388-93. PubMed ID: 8583779 [TBL] [Abstract][Full Text] [Related]
17. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis]. Cordioli E; Virgilio S; Ghirardi R; Martinelli M Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297 [TBL] [Abstract][Full Text] [Related]
18. Effect of dazoxiben, a thromboxane synthetase inhibitor on skin-blood flow following cold challenge in patients with Raynaud's phenomenon. Tindall H; Tooke JE; Menys VC; Martin MF; Davies JA Eur J Clin Invest; 1985 Feb; 15(1):20-3. PubMed ID: 3921380 [TBL] [Abstract][Full Text] [Related]